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Abstract
The parenteral administration of hydrophobic substances in vivo requires the use of organic solvents to
ensure sufficient solubility and avoid precipitation. Dimethyl sulfoxide is commonly used for this purpose.
Based on the common assumption that polyethylene glycol (PEG) is non-toxic, our local regulatory authorities
recently recommended the use of PEG instead. However, mice injected intraperitoneally (i.p.) with PEG 200 at
a dose of 8 mL/kg (i.e. 9 g/kg) did not tolerate PEG 200 well, and half of the animals had to be euthanized. Our
results demonstrate that although PEG 200 is generally considered to be harmless, it can be toxic when
injected i.p. and is painful for the recipient mice. Nevertheless, it can be used as a solvent for repeated
i.p. injections in mice at a dose of 2 mL/kg (i.e. 2.25 g/kg) without obvious signs of systemic toxicity.
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Introduction
To minimise the suffering of experimental animals,
solvents for injections should ideally be isotonic, used
at body temperature and have a neutral pH of 7.0–7.3.1
However, alternative solvents have to be employed if
substances are poorly soluble in aqueous solution.
Dimethyl sulfoxide (DMSO; CAS number 67-68-5)
is commonly used as a vehicle for hydrophobic sub-
stances to improve their solubility and avoid precipita-
tion (Figure 1(a)). DMSO has a relatively low toxicity
when applied systemically, and is rapidly cleared from
the circulation and tissues.2,3 However, the injection of
DMSO causes transient pain. Moreover, DMSO influ-
ences a variety of biological processes, and induces sev-
eral side effects, limiting its range of applicability.4
Polyethylene glycols (PEGs; a-Hydro-o-hydroxypo-
ly(oxy-1,2-ethanediyl); CAS number 25322-68-3) are
synthetic hydrophilic polyethers that consist of repeat-
ing ethylene oxide units. The general chemical formula
of PEGs is H[OCH2CH2]nOH, where n represents the
average number of oxyethylene groups (Figure 1(b)).2
Pharmaceutical grade PEG preparations are mixtures
of polyethers with different molecular weights and
chain lengths. The pharmaceutical term PEG 200
denotes a PEG mixture with an average molecular
weight of 200 g/mol and an average number of 4.2 oxy-
ethylene groups.2 PEGs increase the solubility of poorly
soluble compounds, and represent a potential alterna-
tive to other organic vehicles.2 They are widely used in
pharmaceutical and cosmetic products, and are gener-
ally considered harmless, as they are non-toxic when
applied orally or dermally.2,5–7 Furthermore, PEGs
are used as food additives, and a daily intake of
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10mg/kg bodyweight is considered acceptable.8
However, reports about the toxicity of parenterally
applied PEG in mice are scarce, and it is not widely
accepted that the injection of PEG can be harmful.9–11
We have used DMSO as a solvent for preclinical
parenteral in vivo studies for more than a decade.12–15
In 2017, we applied for permission to inject a test sub-
stance dissolved in DMSO intraperitoneally (i.p.) into
tumour-bearing mice. However, the local regulatory
authorities recommended that DMSO should be
replaced with PEG, which they considered less harmful
than DMSO. Having had no previous experience with
the use of PEG, we followed this recommendation.
Consequently, we used PEG 200 as a vehicle, and
injected it at the approved dose. Unexpectedly, PEG
200 was not tolerated well by the mice, and half of
them had to be euthanized. A subsequent literature
search revealed that the toxicity of parenterally applied
PEG had been reported more than five decades ago.10
As this literature is not widely read, here we highlight
the often overlooked fact that PEG 200 is toxic with a
LD50 of 7.5mL/kg in i.p. injections.
10 Moreover, we
observed that PEG 200 causes pain when injected i.p.,
even at a moderate dose.
Materials and methods
The animal experiment was approved by the local regu-
latory authorities, and was performed according to
German legal requirements.
In control experiments, 16 (eight male) in-house-
bred C57BL/6 J mice aged 12–14 weeks (meanSD
weight males: 29.9 2.2 g; mean weight females:
22.9 1.6 g) were randomly allocated to two groups
with eight animals (four male) each. These groups
were injected subcutaneously with either 5000 or
20,000 syngeneic B16-F10 cells in 100 mL phosphate-
buffered saline per animal. On day 4 post tumour cell
inoculation, the animals were injected i.p. with 8mL/kg
(9 g/kg; approximately 200 mL/animal) undiluted
BioUltra PEG 200 (Sigma–Aldrich, Steinheim,
Germany; lot number: BCBS0153V). The PEG 200
dose used was based on the solubility in PEG 200 of
the chemical substance we intended to test in subse-
quent experiments with other groups of tumour-bear-
ing mice. Treatment was suspended when we observed
that the mice did not tolerate the injected PEG 200, and
was resumed with the surviving mice on day 6 post
tumour cell inoculation, with a reduced PEG
200 dose of 2mL/kg (2.25 g/kg; approximately
50 mL/animal). During the experiment, the animals
were monitored at least four times per day. Tumour
growth was assessed with a calliper twice per week.
Animals were killed by cervical dislocation. The experi-
mental scheme is depicted in Figure 2.
Mice were kept in groups of four in type III macro-
lon filtertop cages (Tecniplast, Hohenpeißenberg,
Germany) containing SAFE fs14 bedding
(Rettenmaier & Söhne, Rosenberg, Germany). Rat/
mouse extruded food (SSNIFF, Soest, Germany) and
sterilised water acidified with HCl (pH 2.8–3.1) were
provided ad libitum. The specific pathogen-free area
was kept at 20C and 30–60% humidity on a 07:00–
20:00 hours light cycle. The health status of the animals
in the facility is routinely assessed by a commercial vet-
erinarian laboratory (mfd Diagnostics, Wendelsheim,
Germany) in serological examinations every three
months (epizootic diarrhoea of infant mice, mouse
hepatitis virus, murine norovirus, minute virus of
mice, Theiler’s encephalomyelitis virus, Pasteurella
pneumotropica) or annually (Clostridium piliforme,
Mousepox, lymphocytic choriomeningitis virus, mouse
adenovirus type 1 and type 2, Mycoplasma pulmonis,
pneumonia virus of mice, Reovirus type 3, Sendai
virus). The serology was found to be negative for the
parameters tested.
Results
PEG 200 is not tolerated well by mice upon
i.p. injection
PEG 200 was injected i.p. at 8mL/kg into the two con-
trol groups of tumour-bearing mice that only received
the solvent PEG 200. Directly after the injection, all 16
animals had contracted flanks, and were obviously in
pain. The flanks remained contracted, and the mice
retreated to the corners of their cages, cowering apath-
etically. This status remained unchanged for several
hours. Eight animals (three male) were moribund, and
Figure 1. Chemical formulae of (a) dimethyl sulfoxide
(DMSO), (b) polyethylene glycol (PEG) and (c) tetraethylene
glycol. (b) In the case of PEG 200 that was used in our
study, n is 4.2.
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were euthanized 24 hours post injection (Table 1),
whereas the remaining eight mice started to recover.
The surviving animals completely recovered without
any sign of discomfort by 48 hours after the injection.
In a subsequent extensive literature search, we found
a single report from 1965 in which the toxicity of PEG
was tested.10 The LD50 of PEG 200 was 7.5mL/kg
when administered i.p. in Swiss albino mice.10 Based
on these data, we reduced the dose to 2mL/kg, and
resumed the injections after 48 hours. The lower dose
was tolerated relatively well, and the experiment was
continued with up to 18 further PEG 200 injections at
2mL/kg doses (Figure 2). Table 2 summarises the
observations upon i.p. injection of 2mL/kg PEG 200,
which suggest transient pain immediately after the
injection, with complete recovery 60minutes post injec-
tion. These observations suggest that PEG 200 can be
injected repeatedly i.p. at a dose of 2mL/kg without
obvious signs of systemic toxicity, but even this dose
causes local pain and suffering.
Discussion
Organic vehicles such as DMSO have higher toxicity
and unwanted side effects compared to isotonic
aqueous vehicles, and the injection of DMSO is more
painful for the recipient animals. During evaluation of
our recent application to perform animal experiments,
the local authorities strongly recommended the use of
PEG, which they considered harmless, with the inten-
tion of replacing DMSO with a vehicle that is better
tolerated. Unaware of its toxicity, we complied with
this recommendation, and injected PEG 200 i.p. into
tumour-bearing mice. Unexpectedly, we observed that
PEG 200 was more harmful than DMSO, that the injec-
tion of PEG 200 caused pain even at a dose of 2mL/kg
and that a dose of 8mL/kg was not tolerated well by
the animals.
While generally considered non-toxic when applied
orally or dermally or when used in cosmetic products,
adverse reactions to PEG have been reported, especially
for PEGs with low molecular weight or when PEG has
been applied to mucous membranes or damaged
skin.2,5–7 For example, three burn patients died due to
renal failure caused by a burn cream containing PEG.16
The toxicity of PEGs injected intravenously as a 5%
solution was found to be very low in rabbits (LD50:
Figure 2. Schematic overview of how the experiment was performed. Two groups of mice, each with four male and four
female animals, were used for the experiment. Group 1 was subcutaneously injected with 5000 syngeneic B16-F10
melanoma cells; group 2 received 20,000 B16-F10 cells. On day 4 post tumour cell inoculation, the animals were
intraperitoneally injected with PEG 200 at 8 mL/kg. The animals did not tolerate the treatment well, and eight animals had
to be euthanized by cervical dislocation. The remaining mice that had recovered from the first PEG injection were then
injected again intraperitoneally on days 6–8, 11–15, 18–22 and 25–29 post tumour cell inoculation with PEG 200 at a dose of
2 mL/kg. The remaining animals were killed on day 29 post tumour cell injection by cervical dislocation.
Table 2. Effects of intraperitoneal injection of PEG 200 at
2 mL/kg in mice.
Time post injection
(minutes) Observations
>1 Signs of pain
5 Signs of pain
20 Flanks contracted;
restless behaviour
45 Flanks contracted; curious
60 Normal behaviour





< , < ,
Group 1 4 4 1 3
Group 2 4 4 2 2
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10,000mg/kg).17 However, few studies have examined
the toxicity of parenterally applied PEG in mice.
Shideman and Procita compared the toxicity of poly-
propylene glycols and PEGs.9 They report a LD50 of
9.2 g/kg for PEG 400 upon i.p. injection into mice – a
value for this size of PEG that is also available in
Scifinder.9,18 In 1965, Worthley and Schott found that
the LD50 of PEG 200 was 7.5mL/kg when administered
i.p. in Swiss albino mice.10 As PEG can reduce plasma
volume without altering osmolality, it has been sug-
gested that the lethal effect of parenterally applied
PEG is caused by hypovolaemic shock.11 We report
here that a single i.p. injection of PEG 200 at a dose
of 8mL/kg (9 g/kg; densityPEG200¼ 1.125 g/mL at
20C) into mice caused pain and was toxic. The lethal-
ity within our population was 50% (8/16 animals), sug-
gesting an LD50 of 8mL/kg, which is slightly above the
LD50 reported by Worthley and Schott for PEG 200,
and slightly below the LD50 determined by Shideman
and Procita for PEG 400.9,10 However, the pain that we
observed directly after the injection was not reported in
previous studies.9,10 Clearly, this pain should be con-
sidered when the suffering of the animals is assessed.
Our observations suggest that animals injected with
PEG i.p. should receive analgesics, although these may
distort experimental outcomes. Similarly, use of alter-
native vehicles requires careful consideration. For
example, vegetable oils that contain linolic acid and
vitamin E influence metastasis in vivo.15,19,20
Nanocarriers can also be toxic and can bias results.21
For example, pegylated phospholipid micelles differen-
tially induce apoptosis in cancerous compared to non-
cancerous cell lines.22
We used a high grade (‘BioUltra’) PEG solution that
is tested to ensure minimal trace impurities below
10mg/kg, except for sodium (200) and potassium
(500).23 Assuming a maximum of 500mg/kg in the
PEG 200 preparation, and given a PEG dose of 9 g
PEG 200/kg and an average weight of 25 g per
mouse, 0.225 g PEG 200 and approximately 0.1125mg
potassium were applied per animal. The LD50 of KCl is
15.925mg/mouse, and no lethality was observed at
12.5mg/mouse.24 Thus, the estimated potassium dose
that we applied is 1/72th below the LD50, making it
highly unlikely that potassium is responsible for the
systemic toxicity that we observed upon injection of
PEG 200.
PEG 200 is a mixture of PEGs with an average
molecular weight of 190–210 g/mol and an average oxy-
ethylene group number of 4.2.2 The predominant spe-
cies in PEG 200 is tetraethylene glycol (CAS number
112-60-7; Figure 1(c)). Due to the manufacturing pro-
cess, PEG species with a lower molecular weight such as
monoethylene glycol (CAS number 107-21-1; 62.07 g/
mol) and diethylene glycol (CAS number 111-46-6;
106.12 g/mol) can be found in tetraethylene glycol and
PEG 200 preparations.25 Monoethylene glycol and
diethylene glycol are toxic.26 When injected i.p. into
mice, the LD50 for monoethylene glycol is 5.62 g/kg,
and the LD50 for diethylene glycol 9.73 g/kg.
27
Although information about the content of monoethy-
lene glycol and diethylene glycol in the BioUltra PEG
solution we used is not available, other similar products
are reported to have a combined monoethylene and
diethylene glycol content of 0.4–7%.28,29 Depending
on the presence and actual concentration of monoethy-
lene diethylene glycol and diethylene glycol in the
BioUltra PEG solution, these two compounds could
conceivably contribute to the toxic effects of PEG 200
that we observed. However, even assuming a mono-
ethylene content of 1% and a diethylene content of
6%, doses of only 0.89 and 0.534 g/kg, respectively,
would have been reached at the beginning of the experi-
ment. These doses represent 1/60 and 1/20 of the LD50
of monoethylene glycol and diethylene glycol, respect-
ively, and would not have been sufficient to cause the
toxic effects alone. However, we cannot rule out a con-
tribution of monoethylene glycol and diethylene glycol
to the pain we observed upon injection of PEG 200.
A general recommendation for injections in experi-
mental animals is that the solutions should have a neu-
tral pH of 7.0–7.3.1 The poor solubility of our intended
test substance meant that undiluted PEG 200 had to be
used. When we measured the pH of the PEG 200 at
room temperature, we found that the pH was between
8.6 and 9.1. However, the impact of pH varies depend-
ing on the route of administration.1 Therefore,
although a contribution of pH to the observed pain
caused by the PEG 200 injections cannot be ruled
out, it is not trivial to predict the actual impact of the
pH on the peritoneum.
Mice injected i.p. with a single dose of 4mL/kg PEG
400 tolerated the treatment, and were killed 1, 5, 8 or
24 h post injection.11 Alanine transaminase (ALT)
levels were temporarily increased, ascites accumulated
and necrosis occurred in the subcapsular regions of the
liver.11 In our experiment, a lower dose of 2mL/kg
PEG 200 (2.25 g/kg) was well tolerated, and no accu-
mulation of fluid in the peritoneal cavity was observed
post-mortem. As we did not measure ALT levels in the
blood or investigate possible hepatic necrosis, we
cannot draw conclusions about possible effects on
the liver.
In summary, PEG 200 is not tolerated well when
injected i.p. into mice at 8mL/kg. At 2mL/kg, PEG
200 still induces local pain but can be administered
repeatedly without obvious signs of systemic toxicity.
Due to the serendipitous nature of our observations, we
did not use injection with control substances to assess the
toxicity of PEG 200, and therefore our study can formally
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only be considered observational rather than conclusive.
Nevertheless, our observations highlight the fact that
although PEGs are considered harmless and non-toxic
when applied orally or dermally to the undamaged
skin, i.p. injections of pure, undiluted PEG are not
safe at a dose of 8mL/kg, and cause pain even at a
dose of 2mL/kg.
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Résumé
L’administration parentérale de substances hydrophobes in vivo nécessite l’utilisation de solvants organiques
pour assurer une solubilité suffisante et éviter la précipitation. Le diméthylsulfoxyde (DMSO) est couramment
utilisé à cette fin. Le polyéthylène glycol (PEG) est généralement considéré comme non toxique, aussi nos
autorités de réglementation locales ont récemment recommandé son utilisation à la place du DMSO.
Cependant, les souris ayant reçu des injections de 8 mL/kg (c.-à-d. 9 g/kg) de PEG 200 par voie intrapérito-
néale n’ont pas bien tolérer le PEG 200, et la moitié des animaux ont dû être euthanasiés. Nos résultats
montrent que, bien que le PEG 200 soit généralement considéré comme inoffensif, il peut s’avérer toxique
lorsqu’il est injecté par voie intrapéritonéale, et douloureux pour les souris. Il peut toutefois être utilisé
comme solvant pour injecter des souris de manière répétée par voie intrapéritonéale à la dose de 2 mL/kg
(c.-à-d. 2,25 g/kg) sans signes de toxicité systémique.
Abstract
Die parenterale Verabreichung hydrophober Substanzen in vivo erfordert den Einsatz organischer
Lösungsmittel, um eine ausreichende Löslichkeit zu gewährleisten und Präzipitationen zu vermeiden. Zu
diesem Zweck wird häufig Dimethylsulfoxid (DMSO) verwendet. Ausgehend von der Annahme, dass PEG im
Allgemeinen ungiftig ist, wurde uns von der Zulassungsbehörde die Verwendung von Polyethylenglykol (PEG)
an Stelle von DMSO nahegelegt. Allerdings vertrugen Mäuse, denen PEG 200 in einer Dosis von 8 mL/kg
(entspricht 9 g/kg) intraperitoneal verabreicht wurde, die Substanz nicht. Als Folge musste die Hälfte der
Tiere getötet werden. Unsere Ergebnisse zeigen, dass PEG 200, obgleich allgemein als unbedenklich ange-
sehen, bei intraperitonealer Injektion toxisch sein kann und darüber hinaus für die Empfängermäuse
schmerzhaft ist. PEG 200 kann aber bei wiederholten intraperitonealen Injektionen bei Mäusen in einer
Dosis von 2 mL/kg (entspricht 2,25 g/kg) als Lösungsmittel verwendet werden, ohne dass dabei offensich-
tliche Anzeichen einer systemischen Toxizität auftreten.
Abstracto
La administración parenteral de sustancias hidrofóbicas in vivo requiere el uso de disolventes orgánicos para
asegurar una solubilidad suficiente y evitar la precipitación. El dimetilsulfóxido (DMSO) se utiliza comúnmente
para este fin. Basándose en el supuesto común de que el PEG (Polietilenglicol) no es tóxico, nuestras
autoridades reguladoras locales recomendaron recientemente el uso de PEG en su lugar. Sin embargo,
los ratones inyectados por vı́a intraperitoneal con PEG 200 a una dosis de 8 mL/kg (es decir, 9 g/kg) no
toleraron bien el PEG 200, y la mitad de los animales tuvieron que ser sacrificados. Nuestros resultados
demuestran que aunque el PEG 200 se considera generalmente inofensivo, puede ser tóxico cuando se
inyecta por vı́a intraperitoneal, y es doloroso para los ratones receptores. No obstante, puede utilizarse
como disolvente para inyecciones intraperitoneales repetidas en ratones a una dosis de 2 mL/kg (es decir,
2,25 g/kg) sin signos evidentes de toxicidad sistémica.
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